Enzo Biochem settles with Chugai and bioMerieux:
This article was originally published in Clinica
Executive Summary
Enzo Biochem has settled a patent dispute with Chugai Pharmaceutical of Japan, which was acquired last year by Roche, and bioMerieux's US arm in Durham, North Carolina. Roche says the dispute will have no financial effect on it, because it concerned the Gen-Probe unit that has now been spun out. Farmingdale, New York-based Enzo's law suit, which relates to its US patent No 4,900,659 covering genetic probes for detecting Neisseria gonorrhoeae, continues with Gen-Probe and another defendant, Becton Dickinson. The terms of the settlement were not disclosed.
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.